Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

Core Insights - Allarity Therapeutics has developed a new Drug Response Predictor (DRP) for the monoclonal antibody daratumumab, aimed at identifying multiple myeloma patients who are most likely to benefit from the treatment [1][2][3] Group 1: Drug Response Predictor Development - The daratumumab DRP was created by analyzing gene expression patterns related to sensitivity and resistance to daratumumab-induced antibody-dependent cellular cytotoxicity (ADCC), identifying 53 genes in total [2] - The DRP utilizes single-cell RNA sequencing data and clinical response information from the KYDAR trial, demonstrating its ability to predict treatment outcomes and survival in multiple myeloma patients [2] Group 2: Company Strategy and Technology - The introduction of the daratumumab DRP marks the first application of Allarity's DRP technology for an antibody therapy, expanding its portfolio beyond small-molecule drugs [3] - The company aims to position itself as a strategic partner for third parties looking to target the right patients with existing cancer therapies, enhancing its potential for future collaborations [3] Group 3: Clinical and Regulatory Context - Daratumumab is already approved by the FDA and EMA for treating multiple myeloma, marketed under the brand name Darzalex [5] - Allarity has developed DRPs for numerous anticancer drugs, including its lead program, stenoparib, which is in Phase 2 development for advanced ovarian cancer [6][11]